A parapsychia that reduces male sexual desire; Inoperable prostate cancer; Signs of severe androgenization in women, such as very severe hirsutism, androgen-dependent severe hair loss leading to baldness (severe androgenic alopecia), often accompanied by severe acne and/or seborrhea.
Usage and dosage:
The general treatment starts with 1 piece of bid and can be increased to 2 pieces of bid if needed, or even 2 pieces of tid in the short term. The medicine should be swallowed with a small amount of liquid after meals. When satisfactory results are achieved, the efficacy should be maintained with the lowest possible dose, often twice a day, with half a tablet each time sufficient. When a maintenance dose is established or discontinued, it should be tapered not suddenly but gradually, and the daily dose should be reduced by 1 tablet or preferably half tablet at intervals of several weeks. In order to stabilize the therapeutic effect, the use of this drug must be extended for a period of time, and if possible, accompanied by psychotherapy.
Inoperable prostate cancer
To eliminate the effects of adrenocortical androgens after orchiectomy: 2 tablets 1-2 times daily (i.e. 100-200 mg).
Without orchiectomy: 2 tablets 2-3 times daily (i.e. 200-300 mg). The therapeutic dose should not be altered or interrupted after symptoms change or abate.
Treatment with a gonadotropin-releasing hormone agonist (LH-Rha) to reduce the initial increase in male sex hormones: start with this drug alone, 2 tablets 2 times daily (i.e. 200 mg) for 5-7 days, followed by 2 tablets 2 times daily (200 mg) with one LH-Rha for 3-4 weeks.
To eliminate the effect of adrenal cortical androgens during LH-Rha therapy: Continuous anti-androgen therapy, take 2 tablets of this drug 1-2 times a day (i.e. 100-200 mg).
Signs of severe androgenization in women, such as very severe hirsutism, androgen-dependent severe hair loss leading to baldness (severe androgenic alopecia), often accompanied by severe acne and/or seborrhea. For women of childbearing age, treatment should start on the first day of the menstrual cycle (i.e. the first day of bleeding), and only women with amenorrhea can start medication immediately. In this case, the first day of treatment is considered the first day of the cycle and is routinely observed according to the following recommended usages. On days 1-10 of the cycle, 2 tablets of this drug are swallowed with water every day after meals, in addition to preparations containing estrogen and progesterone, such as 1 oral contraceptive pill per day from days 1-21 of the menstrual cycle, to provide the necessary contraceptive protection and stabilize the menstrual cycle. Women receiving periodic combination therapy should take medication at a fixed time each day. If it is longer than 12 hours, the contraceptive effect of this cycle may be reduced, but this drug and oral contraceptives should still be taken according to the instructions to avoid early bleeding in this cycle. Missed tablets can be ignored, but non-hormonal contraceptive methods should be used for the rest of the cycle (except safe period and temperature measurement). There is an observation period of 7 days after 21 days of medication cessation, during which withdrawal bleeding will occur, and the next cycle of combination therapy will be started exactly 4 weeks after the start of the first course, that is, on the same day of the week, regardless of whether bleeding has stopped. If bleeding does not occur during discontinuation, the necessary diagnostic tests should be performed. After clinical symptoms improve, the daily dose of this drug can be reduced to 1 or half tablet during the first 10 days of combination therapy, which may be sufficient for oral contraceptives alone. Postmenopausal or hysterectomy patients can use this drug alone. Depending on the severity of symptoms, the average dose of the drug should be 1 to half a tablet once a day for 21 days, followed by 7 days of discontinuation.
Matters needing attention:
1. Pregnancy, lactation, liver disease, previous history of jaundice or persistent pruritus during pregnancy, history of herpes during pregnancy, Dubin-Johnson syndrome, Rotor syndrome, previous or existing liver tumor (not due to metastatic prostate cancer), wasting disease (except inoperable prostate cancer), major chronic depression, Previous or existing thromboembolic conditions, severe diabetes with vascular changes, and sickle cell anemia are contraindosed.
2. Patients with prostate cancer who have a history of thromboembolism, sickle cell anemia or severe diabetes with vascular changes must carefully weigh the pros and cons of each case before using this drug.
3, for the occupation requires a high degree of concentration of patients (such as drivers, machine operators) should be used with caution, this drug can cause fatigue, decreased energy, may also affect the ability to concentrate.
Audited Supplier 
){kind=link}
){kind=link}